Cyclosporin

Abstract

The cyclosporin family of secondary metabolites isolated from the fungus Tolypocladium inflatum is characterised by a cyclopeptide structure consisting of an 11‐membered amino acid ring, containing N‐methylated peptide bonds. Parent cyclosporin A (CsA) is a drug widely used to prevent and treat rejection episodes after organ transplantation and can be used in autoimmune diseases. It is immunosuppressive, anti‐inflammatory, antichemotactic and antiviral but CsA‐induced immunosuppression and nephrotoxicity cause limitations in its general use in clinical practice. In lymphoid cells, after binding to its receptor cyclophilin A (CypA), CsA acts via gain‐of‐function inhibiting the protein phosphatase calcineurin and thus the transcription of several cytokines. Nonimmunosuppressive CsA derivatives lacking gain‐of‐function in the cell result from semisynthetic procedures mostly modifying its MeLeu‐4 side chain. These derivatives strongly inhibit the prolyl cis/trans isomerase activity of CypA, which, in turn, is a host cell factor for viral infections and other pathophysiological states in human diseases.

Key Concepts:

  • Beside its use in transplantation medicine, treatment of other human disorders with CsA has some limitations due to immunosuppression and toxicity.

  • Immunosuppressive activity can be successfully removed from the cyclosporine molecule using a variety of Leu‐4 substituted CsA derivatives.

  • Nonimmunosuppressive CsA derivatives can retain the high potency of CsA in inhibiting the prolyl cis/trans isomerase activity of the CsA receptor CypA.

  • Nonimmunsuppressive CsA derivatives have been utilised to launch clinical phase studies for the treatment of hepatitis C virus infections.

  • A broad antiviral activity of nonimmunosuppressive CsA derivatives in addition to the anti‐HCV profile has been suggested.

  • CsA derivatives have been designed to target cyclophilins in specific tissues and organelles.

  • Extracellularly restricted CsA derivatives are potent drug candidates to combat chronic inflammations.

Keywords: immunosuppression; inhibition; cyclophilin; calcineurin; viral infection; inflammation

Figure 1.

CsA chemical structure: CsA residues are: MeBmt; Abu; Sar, sarcosine; MeLeu, N‐methyl leucine; Val, valine; Ala, alanine; D‐Ala, D‐alanine; MeVal, N‐methyl valine.

Figure 2.

Conformations of CsAs in the unbound form (a) (Loosli et al., ) and in complex with Cyp18 (b) (Huai et al., ). The peptide bond between MeLeu‐9 and MeLeu‐10 in cis or trans conformations are coloured yellow. The β‐II′ turn in the unbound CsA form is coloured cyan. Hydrogen bonds are indicated as dashes.

Reproduced from Huai et al.2002.
Figure 3.

Molecular basis of CsA immunosuppressive activity. T‐cell activation and cytokine transcription is suppressed by inhibition of CaN catalysed NFAT dephosphorylation by binding of CsA/CypA complex to CaN.

Reproduced from Liu et al.1991.
Figure 4.

Ribbon representation of CyPA–CsA–CaN ternary complex (Huai et al., ). Colour codes are CaNA, red; CaNB, orange; CsA, green; CypA, blue. The ternary complex is visualised using software PyMOL Molecular Graphics System, Version 1.3.

Reproduced from Huai et al.2002.
Figure 5.

Structures of NIM‐811, Debio‐025 (Alisporivir) and SCY‐635. Structural elements that are added to the core CsA structure are in bold red. Structural elements that are present in CsA but not in the corresponding analogues are presented in grey colour.

close

References

Amor KT, Ryan C and Menter A (2010) The use of cyclosporine in dermatology: part I. Journal of the American Academy of Dermatology 63(6): 925–949.

Aouali N, Eddabra L, Macadre J and Morjani H (2005) Immunosuppressors and reversion of multidrug‐resistance. Critical Reviews in Oncolology and Hematology 56(1): 61–70.

Azouzi S, Morandat S and El Kirat K (2011) The potent antimalarial peptide cyclosporin A induces the aggregation and permeabilization of sphingomyelin‐rich membranes. Langmuir 27(15): 9465–9472.

Balsley MA, Malesevic M, Stemmy EJ et al. (2010) A cell‐impermeable cyclosporine a derivative reduces pathology in a mouse model of allergic lung inflammation. Journal of Immunology 185(12): 7663–7670.

Baugh J and Gallay P (2012) Cyclophilin involvement in the replication of hepatitis C virus and other viruses. Biological Chemistry 393(7): 579–587.

Baumgrass R, Zhang Y, Erdmann F et al. (2004) Substitution in position 3 of cyclosporin A abolishes the cyclophilin‐mediated gain‐of‐function mechanism but not immunosuppression. Journal of Biological Chemistry 279(4): 2470–2479.

Bell A, Monaghan P and Page AP (2006) Peptidyl‐prolyl cis–trans isomerases (immunophilins) and their roles in parasite biochemistry, host‐parasite interaction and antiparasitic drug action. International Journal for Parasitology 36(3): 261–276.

Bell RD, Winkler EA, Singh I et al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485(7399): 512–516.

Bernardi F, Gaggelli E, Molteni E et al. (2006) H‐1 and C‐13‐NMR and molecular dynamics studies of cyclosporin A interacting with magnesium(II) or cerium(III) in acetonitrile. Conformational changes and cis‐trans conversion of peptide bonds. Biophysical Journal 90(4): 1350–1361.

Billich A, Hammerschmid, F Peichl P et al. (1995) Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein‐cyclophilin A interactions. Journal of Virology 69(4): 2451–2461.

Borel JF, Feurer C, Gubler HU and Stahelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6(4): 468–475.

Bua J, Fichera LE, Fuchs AG et al. (2008) Anti‐Trypanosoma cruzi effects of cyclosporin A derivatives: possible role of a P‐glycoprotein and parasite cyclophilins. Parasitology 135(2): 217–228.

Ciesek S, Steinmann E, Wedemeyer H et al. (2009) Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 50(5): 1638–1645.

Coaker G, Falick A and Staskawicz B (2005) Activation of a phytopathogenic bacterial effector protein by a eukaryotic cyclophilin. Science 308(5721): 548–550.

Czogalla A (2009) Oral cyclosporine A – the current picture of its liposomal and other delivery systems. Cellular & Molecular Biology Letters 14(1): 139–152.

Dreyfuss M, Harri E, Hofmann H et al. (1976) Cyclosporin‐A and C new metabolites from Trichoderma–Polysporum (Link Ex Pers) Rifai. European Journal of Applied Microbiology 3(2): 125–133.

Dube H, Selwood D, Malouitre S et al. (2012) A mitochondrial‐targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes. Biochemical Journal 441(3): 901–907.

Dumont FJ (2004) ISAtx‐247 (Isotechnika/Roche). Current Opinion in Investigational Drugs 5(5): 542–550.

Eltayar N, Mark AE, Vallat P et al. (1993) Solvent‐dependent conformation and hydrogen‐bonding capacity of cyclosporine‐A – Evidence from partition‐coefficients and molecular‐dynamics simulations. Journal of Medicinal Chemistry 36(24): 3757–3764.

Fischer G, Bang H and Mech C (1984) Determination of enzymatic catalysis for the cis‐trans‐isomerization of peptide bonds in proline‐containing peptides. Biomedica Biochimica Acta 43 (10): 1101–1111.

Gaither LA, Borawski J, Anderson LJ et al. (2010) Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 397(1): 43–55.

Gallay PA (2009) Cyclophilin Inhibitors. Clinics in Liver Disease 13(3): 403–417.

Gallay PA and Lin K (2013) Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Design, Development and Therapy 7: 105–115.

Hamel AR, Hubler F and Mutter M (2005) Water‐soluble prodrugs of cyclosporine A with tailored conversion rates. Journal of Peptide Research 65(3): 364–374.

Handschumacher RE, Harding MW, Rice J, Drugge RJ and Speicher DW (1984) Cyclophilin – A Specific Cytosolic Binding‐Protein for Cyclosporin‐A. Science 226(4674): 544–547.

Hong F, Lee J, Song J‐W et al. (2002) Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl‐prolyl cis‐trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A‐induced cytotoxicity. FASEB Journal 16(10): 1633–1635.

Hopkins S, Scorneaux B, Huang Z et al. (2010) SCY‐635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrobial Agents and Chemotherapy 54(2): 660–672.

Hoppert M, Gentzsch C and Schorgendorfer K (2001) Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum. Archives of Microbiology 176(4): 285–293.

Huai Q, Kim HY, Liu Y et al. (2002) Crystal structure of calcineurin‐cyclophilin‐cyclosporin shows common but distinct recognition of immunophilin‐drug complexes. Proceedings of the National Academy of Sciences of the USA 99(19): 12037–12042.

Ismailos G, Reppas C, Dressman JB and Macheras P (1991) Unusual solubility behaviour of cyclosporin A in aqueous media. Journal of Pharmacy and Pharmacology 43(4): 287–289.

Janowski B and Fischer G (1997) Modulation of cyclosporin A cyclophilin interactions by drug vehicles. Bioorganic and Medicinal Chemistry 5(1): 179–186.

Jeffery JR (1991) Cyclosporine analogues. Clinical Biochemistry 24(1): 15–21.

Jin L and Harrison SC (2002) Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proceedings of the National Academy of Sciences of the USA 99(21): 13522–13526.

Kockx M, Jessup W and Kritharides L (2010) Cyclosporin A and atherosclerosis – cellular pathways in atherogenesis. Pharmacology & Therapeutics 128(1): 106–118.

Landrieu I, Hanoulle X, Bonachera F et al. (2010) Structural basis for the non‐immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry 49(22): 4679–4686.

Lazarova T and Weng ZG (2003) Cyclosporin A analogues: recent advances. Expert Opinion on Therapeutic Patents 13(9): 1327–1332.

Liu J, Farmer JD, Lane WS et al. (1991) Calcineurin is a common target of cyclophilin–cyclosporine‐A and Fkbp‐Fk506 complexes. Cell 66(4): 807–815.

Loor F, Tiberghien F, Wenandy T, Didier A and Traber R (2002) Cyclosporins: structure‐activity relationships for the inhibition of the human FPR1 formylpeptide receptor. Journal of Medicinal Chemistry 45(21): 4613–4628.

Loosli HR, Kessler H, Oschkinat H et al. (1985) Peptide conformations. Part 31. The conformation of cyclosporin‐a in the crystal and in solution. Helvetica Chimica Acta 68(3): 682–704.

Malesevic M, Kuhling J, Erdmann F et al. (2010) A cyclosporin derivative discriminates between Extracellular and Intracellular Cyclophilins. Angewandte Chemie‐International Edition 49(1): 213–215.

Mikol V, Kallen J, Pflügl G and Walkinshaw MD (1993) X‐ray structure of a monomeric cyclophilin A‐cyclosporin A crystal complex at 2.1 A resolution. Journal of Molecular Biology 234(4): 1119–1130.

Nacev BA, Low WK, Huang Z et al. (2011) A calcineurin‐independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog. Journal of Pharmacology and Experimental Therapeutics 228(2): 466–475.

Nobili S, Landini I, Giglioni B and Mini E (2006) Pharmacological strategies for overcoming multidrug resistance. Current Drug Targets 7(7): 861–879.

Olyaei AJ, de Mattos AM and Bennett W (2001) Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Current Opinion in Critical Care 7(6): 384–389.

Osman MM, Lulic D, Glover L et al. (2011) Cyclosporine‐A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides 45(6): 359–368.

Ozbay A, Karamperis N and Jorgensen KA (2007) A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Current Clinical Pharmacology 2(3): 244–248.

Prell E, Kahlert V, Rücknagel KP, Malešević M and Fischer G (2013) Fine tuning the inhibition profile of cyclosporine A by derivatization of the MeBmt residue. ChemBioChem 14(1): 63–65.

Quesniaux VF, Schreier MH, Wenger RM et al. (1987) Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. European Journal of Immunology 17(9): 1359–1365.

Rentzsch A, Kahlert V, Jahreis G et al. (2013) Identification of prolyl oligopeptidase as a cyclosporine‐sensitive protease by screening of mouse liver extracts. Biological Chemistry 394(8): 1057–1067.

Rothbard JB, Garlington S, Lin Q et al. (2000) Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nature Medicine 6(11): 1253–1257.

Scribner A, Houck D, Huang Z et al. (2010) Synthesis and biological evaluation of [D‐lysine]8cyclosporin A analogs as potential anti‐HCV agents. Bioorganic and Medicinal Chemistry Letters 20(22): 6542–6546.

Seizer P, Klingel K, Sauter M et al. (2012) Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3‐induced myocarditis. Journal of Molecular and Cellular Cardiology 53(1): 6–14.

Stewart T, Tsai SC, Grayson H, Henderson R and Opelz G (1995) Incidence of de‐novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346(8978): 796–798.

Theuerkorn M, Fischer G and Schiene‐Fischer C (2011) Prolyl cis/trans isomerase signalling pathways in cancer. Current Opinion in Pharmacology 11(4): 281–287.

Vogel KW, Briesewitz R, Wandless TJ and Crabtree GR (2001) Calcineurin inhibitors and the generalization of the presenting protein strategy. Advances in Protein Chemistry 56: 253–291.

Wenger RM (1985) Synthesis of cyclosporine and analogs – structural requirements for immunosuppressive activity. Angewandte Chemie‐International Edition 24(2): 77–85.

West GM, Tucker CL, Xu T et al. (2010) Quantitative proteomics approach for identifying protein–drug interactions in complex mixtures using protein stability measurements. Proceedings of the National Academy of Sciences of the USA 107(20): 9078–9082.

Yurchenko V, Constant S, Eisenmesser E and Bukrinsky M (2010) Cyclophilin‐CD147 interactions: a new target for anti‐inflammatory therapeutics. Clinical and Experimental Immunology 160(3): 305–317.

Zhang Y, Baumgrass R, Schutkowski M and Fischer G (2004) Branches on the alpha‐C atom of cyclosporin A residue 3 result in direct calcineurin inhibition and rapid cyclophilin 18 binding. Chembiochem 5(7): 1006–1009.

Further Reading

Georgel P, Schuster C, Zeisel MB et al. (2010) Virus–host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends in Molecular Medicine 16(6): 277–286.

Kahan BD (2009) Forty years of publication of transplantation proceedings – the second decade: the cyclosporine revolution. Transplantation Proceedings 41(5): 1423–1437.

Kallen J, Mikol V, Quesniaux VFJ et al. (2008) Cyclosporins: recent developments in biosynthesis, pharmacology and biology, and clinical applications. In: Rehm HJ and Reed G (eds) Biotechnology: Products of Secondary Metabolism, vol. 7, 2nd edn, pp 535–591. Weinheim: John Wiley & Sons, Ltd.

Kroemer G, Galluzzi L and Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiological Reviews 87(1): 99–163.

Schiene‐Fischer C, Aumuller T and Fischer G (2013) Peptide bond cis/trans isomerases: a biocatalysis perspective of conformational dynamics in proteins. Topics in Current Chemistry 328: 35–67.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Fischer, Gunter, and Malešević, Miroslav(Sep 2013) Cyclosporin. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0024215]